AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has achieved statistically significant and clinically meaningful improvement in treating hyperkalaemia in patients with end-stage renal disease (ESRD) on haemodialysis in phase 111b Dialize trial.
Janssen Pharmaceutical’s TREMFYA (guselkumab) succeeded in the phase 3 Discover programme by meeting the primary endpoints of American College of Rheumatology 20% improvement (ACR20) at week 24 in adult patients with active moderate to severe psoriatic arthritis (PsA).
Corvidia Therapeutics, a clinical stage biotechnology company, announced the initiation of patient screening for a Phase 2b dose-finding study of ziltivekimab.
Pfizer has announced positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA).
Novartis announced that its Cosentyx (secukinumab) has achieved its primary and key secondary endpoint in the Maximise study of psoriatic arthritis (PsA).
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
ProtoKinetix, announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type-1 diabetes.
AstraZeneca’s blood cancer drug Calquence (acalabrutinib) in combination with obinutuzumab met the primary endpoint at interim analysis in the phase 3 ELEVATE-TN trial in previously-untreated chronic lymphocytic leukaemia (CLL).
Novartis has announced new early stage histology data in kidney transplantation, suggesting that with investigational compound iscalimab (CFZ533) it may be possible to prolong the durability of transplanted kidneys as well as to potentially improve long-term outcomes for kidney transplant patients.
Goldfinch Bio has initiated dosing in a Phase 1 clinical trial evaluating GFB-887, its subtype-selective, small molecule TRPC5 inhibitor, as a potential treatment for kidney diseases associated with proteinuria and progressive renal dysfunction including focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD) and diabetic nephropathy (DN).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.